Literature DB >> 18312290

Cardiotrophin-1 enhances regeneration of cirrhotic liver remnant after hepatectomy through promotion of angiogenesis and cell proliferation.

Zhen Fan Yang1, Chi Keung Lau, Patricia Ngai, Shuk Pik Lam, David W Ho, Ronnie Tung-Ping Poon, Sheung Tat Fan.   

Abstract

BACKGROUND/AIM: Hepatic resection is not applicable to a certain proportion of hepatocellular carcinoma patients owing to an insufficient liver function reserve. The present study was designed to investigate the effects of cardiotrophin-1 (CT-1) on improving the function of CCl(4)-induced cirrhotic liver remnant after major hepatectomy.
METHODS: CT-1 was administered to rats after hepatectomy according to different protocols.
RESULTS: A double-dose CT-1 protocol improved liver function, enlarged the volume of liver remnant, upregulated the expression of von Willebrand factor and increased the number of BrdU(+) or Ki-67(+) hepatocytes. Administration of CT-1 enhanced the expression of nuclear factor-kappaB (P65), vascular endothelial growth factor (VEGF), CyclinD1 and p42/44 in the liver remnant. However, the effects of CT-1 were blocked by a VEGF receptor blocker, PTK787. Although the expression of gp130, a receptor of CT-1, was downregulated in the diseased hepatocytes isolated from the cirrhotic liver, CT-1 could still stimulate the cell proliferation. CT-1 administration enhanced the expression of P65 and VEGF in the diseased hepatocytes, but the augmented P65 and VEGF expression was blocked by PTK787 administration.
CONCLUSION: Short-term administration of CT-1 could improve the function of cirrhotic liver remnant and stimulate liver regeneration through promotion of angiogenesis and cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18312290     DOI: 10.1111/j.1478-3231.2008.01687.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  7 in total

1.  1,4-Bis[2-(3,5-dichloropyridyloxy)]benzene induces substantial hyperplasia in fibrotic mouse liver.

Authors:  Edina Bugyik; Katalin Dezso; Eszter Turányi; Kinga Szurián; Sándor Paku; Peter Nagy
Journal:  Int J Exp Pathol       Date:  2012-01-14       Impact factor: 1.925

Review 2.  Halofuginone for fibrosis, regeneration and cancer in the gastrointestinal tract.

Authors:  Mark Pines
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

3.  Transcriptomic Analysis of Breast Cancer Patients Sensitive and Resistant to Chemotherapy: Looking for Overall Survival and Drug Resistance Biomarkers.

Authors:  Carlos A Barrón-Gallardo; Mariel Garcia-Chagollán; Andres J Morán-Mendoza; Raul Delgadillo-Cristerna; María G Martínez-Silva; Adriana Aguilar-Lemarroy; Luis F Jave-Suárez
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

4.  Methylation profile of single hepatocytes derived from hepatitis B virus-related hepatocellular carcinoma.

Authors:  Ran Tao; Jun Li; Jiaojiao Xin; Jian Wu; Jing Guo; Liyuan Zhang; Longyan Jiang; Wu Zhang; Zhe Yang; Lanjuan Li
Journal:  PLoS One       Date:  2011-05-23       Impact factor: 3.240

5.  Exosomes Derived From CTF1-Modified Bone Marrow Stem Cells Promote Endometrial Regeneration and Restore Fertility.

Authors:  Qianqian Zhu; Shengluan Tang; Yanwen Zhu; Di Chen; Jialyu Huang; Jiaying Lin
Journal:  Front Bioeng Biotechnol       Date:  2022-04-13

Review 6.  New insights into IL-6 family cytokines in metabolism, hepatology and gastroenterology.

Authors:  Maria D Giraldez; David Carneros; Christoph Garbers; Stefan Rose-John; Matilde Bustos
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-07-01       Impact factor: 46.802

7.  Cardiotrophin-1 determines liver engraftment of syngenic colon carcinoma cells through an immune system-mediated mechanism.

Authors:  Matilde Bustos; Juan Dubrot; Eduardo Martinez-Anso; Eduardo Larequi; David Castaño; Asis Palazon; Idoia Belza; Miguel F Sanmamed; Jose Luis Perez-Gracia; Carlos Ortiz de Solorzano; Carlos Alfaro; Ignacio Melero
Journal:  Oncoimmunology       Date:  2012-12-01       Impact factor: 8.110

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.